Compare Globus Medical Inc. Class A Common Stock (GMED) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Quantumscape Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Quantumscape Corp trades at $3.88 (market cap $2.55B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 4× Quantumscape Corp's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Quantumscape Corp for 37 Days on average.
| GMED | QS | |
|---|---|---|
Market Cap | $10.25B | $2.55B |
Volume | 1,108,124 | 12,145,789 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $18.44 |
52-Week Low | $58.33 | $3.93 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $9.76B | $1.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
QuantumScape (QS) trades at $3.93, down 7.96% today, reflecting ongoing investor skepticism about its path to commercialization. The company remains pre-revenue with significant losses (-$435.05M net income in 2025) and negative profitability metrics (ROE -39.08%). Technical indicators show a bearish trend with oversold RSI readings, while analyst consensus leans heavily toward Hold (72.73%) with a $10.35 price target suggesting potential upside if execution improves.
QS faces substantial execution risk with commercialization delayed until at least 2029 and intense competition in solid-state batteries. The stock offers high-risk speculative potential for investors betting on breakthrough technology adoption, but requires patience through years of cash burn and dependency on future manufacturing success with partners like Volkswagen.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
